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Editorial View: 
Massive hemorrhage originates from severe injury of blood vessels caused by 
major trauma or surgery, an underlying medical condition, or any combination 
thereof. If not diagnosed and treated readily, patients exsanguinate and die from 
hypovolemic shock. In this issue of ANESTHESIOLOGY, Bolliger et al.1 review the 
mechanisms of coagulopathy in massive hemorrhage with a special emphasis on 
hemodilutional effects of fluid therapy on thrombin generation, fibrin polymerization 
and fibrinolysis. A proper understanding of the complex pathophysiology of 
coagulopathy in massive bleeding patients is essential for effective treatment. The 
coagulation system represents a delicate balance between pro- and anti-coagulant 
as well as pro- and anti-fibrinolytic protein activities. Modern coagulation 
management of bleeding patients implies an ongoing monitoring of the coagulation 
status with subsequent individual and goal-directed treatment. The key to success in 
terms of patient outcome is to keep the above mentioned four elements of the 
coagulation system in an optimal equilibrium so that bleeding is adequately controlled 
without thromboembolic adverse events.2 
The coagulation system is a complex network of interacting proteins and cells 
with extensive sensitivity, amplification and control pathways. For any given patient, 
there is no simple answer to coagulation management, but instead, optimal 
coagulation intervention and management needs to be defined for each patient.3 
Advanced coagulation monitoring will employ a combination of routine 
laboratory coagulation tests, single factor measurements and whole blood, point of 
care coagulation testing, always keeping in mind the patient’s history and clinical 
findings.4 Whole blood coagulation tests like Thrombelastography® (Haemonetics 
Corporation, Braintree, MA) or rotation Thromboelastometry® (Tem International 
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GmbH, Munich, Germany) may overcome some of the limitations of routine 
laboratory coagulation tests and are increasingly being used in massive bleeding 
patients. With minimal time delays, they provide valuable information on overall 
kinetics of clot formation, clot strength, platelet function and overt fibrinolysis in whole 
blood.5 However, these tests are still in vitro assays; they do not reflect in vivo 
contributions of local tissue and the endothelium, tissue factor bearing cells, and 
blood flow to the naturally occurring coagulation process. Therefore, any coagulation 
test requires skilled interpretation and clinical correlation in evaluating its significance 
for bleeding or thrombosis. 
Patients with massive hemorrhage become coagulopathic due to several 
mechanisms. Trauma and shock directly activate the thrombomodulin-protein C 
pathway resulting in the acute coagulopathy of trauma and shock.6-8 Thereby, key 
players of the propagation phase of coagulation, the tenase (VIIIa-IXa) and 
prothrombinase (Xa-Va) complex are getting degraded and inactivated by activated 
protein C. Furthermore, plasminogen activator inhibitor 1, the principal inhibitor of 
tissue plasminogen activator and urokinase, activators of plasminogen and hence 
fibrinolysis is consumed through activated protein C, resulting in increased 
fibrinolysis. The developing coagulopathy then gets worse through the better known 
pathogenetic factors: consumption and dilution of coagulation factors, hypothermia 
and acidosis. 
Fibrinogen is the substrate of coagulation and is usually the first coagulation 
factor to become critically low in massive bleeding.2 According to Hiippala et al.,9 
fibrinogen levels fall below 1 g/L after a loss of 150% of the calculated blood volume. 
Factor II, V, VII and platelet levels become critical later, after a loss of >200% of the 
blood volume. However, these figures are very general and do not help greatly in the 
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individual case. In addition, the arbitrary definition of the critical level determines 
when the corresponding level will be reached i.e. after what blood volume loss.  
If patients present with clinical and objective signs of coagulopathic bleeding, 
treatment with allogeneic blood products (fresh frozen plasma, cryoprecipitate, 
platelet concentrates), factor concentrates, pharmacological interventions or a 
combination thereof has to be initiated. Evidence-based recommendations, like the 
one from the multidisciplinary Task Force for Advanced bleeding Care in Trauma,2 
updated in 2010 are very helpful for optimal patient care. One request of the review 
by Bolliger et al.1 is that the efficacy and safety of novel hemostatic therapies like 
factors concentrates are to be assessed in clinical studies. This is certainly correct, 
but this also applies for the traditional use of fresh frozen plasma, cryoprecipitate and 
platelets. 
Transfusion of allogeneic blood products is independently associated with 
increased mortality and major adverse cardiac and non-cardiac outcomes.10 One 
strategy to reduce bleeding and avoid allogeneic blood transfusion in surgical 
patients at increased risk of bleeding is the use of anti-fibrinolytics. For almost two 
decades, published literature demonstrated the relative safety and efficacy of 
aprotinin, a nonspecific serine protease inhibitor especially in adult cardiac surgical 
patients at increased risk of bleeding. However, since the Blood Conservation Using 
Anti-fibrinolytics in a Randomized Trial11 has been published in 2007, aprotinin has 
been withdrawn from the market. The Blood Conservation Using Anti-fibrinolytics in a 
Randomized Trial represented the largest prospective, randomized, blinded head-to-
head comparison of 3 major anti-fibrinolytic agents in current clinical usage.12 The 
study was terminated early because of a trend towards higher mortality in patients 
treated with aprotinin.11,12  
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Since marketing of aprotinin has been suspended, only two anti-fibrinolytics 
remained commercially available in the United States and European Union for patient 
use, i.e. ε-aminocaproic acid and tranexamic acid (TXA). Both drugs are lysine 
analogues and inhibit fibrinolysis by competitively blocking the lysine binding site on 
plasminogen.13 Lysine analogues have shown to reduce blood loss and the need for 
allogeneic red cell transfusion, especially in cardiac, liver and orthopedic surgery. 
The lysine analogues (evidence is stronger for TXA than for ε-aminocaproic acid) 
were probably as effective as aprotinin in most studies but at lower costs.14 The 
results of a cutting-edge landmark trial on the use of TXA in trauma patients, the 
CRASH-2 trial (NCT00375258) have just been published.15  
CRASH-2 is a multicenter (274 hospitals in 40 countries), randomized, blinded 
and placebo controlled trial on the effects of TXA administration on death, vascular 
occlusive events, surgical interventions and blood transfusion in 20,211 adult trauma 
patients.15 Within 8 h of injury, patients with significant hemorrhage, or who were 
considered to be at risk of significant hemorrhage, received either 2 g TXA (1 g 
loading dose, followed by a maintenance dose of 1 g over 8 h) or placebo. TXA 
administration reduced all-cause mortality (14.5 vs. 16.0%; relative risk 0.91, 95% CI 
0.85-0.97; p=0·0035) and the risk of death from hemorrhage (4.9% vs. 5.7%; relative 
risk 0.85, 95% CI 0.76-0.96; p=0·0077) without an increase in fatal or non-fatal 
vascular occlusive events, e.g. stroke, myocardial infarction, deep vein thrombosis or 
pulmonary embolism. Surprisingly however, there was no statistical difference in 
blood transfusion between the groups. The question on how TXA reduced the risk of 
death in bleeding patients remains unanswered by the CRASH-2 study and it may be 
speculated that TXA might have additional, beneficial effects on patient outcome 
beyond simply inhibiting fibrinolysis.16 Another large-scale prospective, randomized, 
double blind, placebo controlled trial on the use of anti-fibrinolytics is planning to 
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enroll 15,000 women with a clinical diagnosis of postpartum hemorrhage (WOMAN 
trial; NCT00872469).17 Data should be available after completion in 2015. 
How should all these aspects translate into perioperative, hemostatic 
management? First, we have to thoroughly understand the pathophysiology of the 
deranged coagulation system in massive bleeding, and in particular understanding 
that blood coagulation does not only consist of pro-coagulant proteins. We always 
have to consider the four elements of the coagulation system and keep them in 
balance, i.e. pro- and anti-coagulant as well as pro- and anti-fibrinolytic ‘sub-
systems’. Second, we have to carefully diagnose the main problem of the disturbed 
coagulation system with patient’s history, clinical findings and adequate blood tests. 
Since blood coagulation may change rapidly during massive hemorrhage, frequent 
re-assessment is necessary. Furthermore, we need to exactly know how to interpret 
the blood tests ordered, what they can tell us and where their limitations are. Third, 
we are to initiate the specific treatment needed by the individual patient early. The 
review by Bolliger et al.1 is an important contribution toward better understanding of 
coagulopathy in massive hemorrhage and hemodilution. The better we know the 
underlying pathophysiology, the better we can diagnose and treat our patients 
targeted to their individual needs. 
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